World Journal of
Pharmaceutical and Life Sciences

LC-MS-BASED INVESTIGATION OF THIARABINE AS A THERAPEUTIC AGENT IN ACUTE MYELOID LEUKEMIA (AML) CELL LINE MODELS

Dr. Syed Ahmed Hussain*, Fariya Sultana, Ghousia Begum, Nada Ahmed Al Amoodi, Bilquis Begum, Somabatthini Shruthi, Ayesha Ayub Khan, Muskan Khatoon

ABSTRACT

This study investigates the therapeutic profile of Thiarabine compared to the standard antileukemic agent Cytarabine using a five-assay in vitro screening panel on acute myeloid leukemia (AML) cell line models. Two assays measured cell viability (Resazurin/Alamar Blue and ATP Luminescence), while three evaluated cytotoxicity (Annexin V/PI, Caspase-3/7 activity, and LDH release). Thiarabine showed 100% cell viability in both assays, indicating minimal cytotoxic effect, while Cytarabine reduced viability to 42% and 38%, respectively. In apoptosis-related assays, Thiarabine induced only 6% apoptotic cells, a caspase-3/7 fold-change of 1.0, and 7% LDH release, contrasting sharply with Cytarabine’s 58%, 3.8-fold increase, and 61% LDH release. These findings suggest that Thiarabine exerts negligible cytotoxic or apoptotic activity under the tested conditions, in contrast to the potent pro-apoptotic action of Cytarabine. Overall, the results confirm Thiarabine’s lower cytotoxicity profile, indicating a potential window for further structure–activity optimization or combinatorial applications in AML therapeutics.

[Full Text Article]   [Download Certificate]